Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.3K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.3K
The Muscular System01:18

The Muscular System

6.9K
The muscular system is essential to the body's overall structure and function, playing a crucial role in movement, stability, and internal processes. It consists of three distinct types of muscle tissue: the skeletal, the smooth, and the cardiac muscles.
6.9K
Therapeutic Index01:13

Therapeutic Index

6.7K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
6.7K
Therapeutic Communication01:30

Therapeutic Communication

7.7K
Communication is a lifelong learning process. Through therapeutic communication, nurses can collect relevant assessment data, provide education and counseling, and interact during nursing interventions. Sending and receiving messages occur through verbal and nonverbal communication techniques and can happen separately or simultaneously.
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
7.7K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.0K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.0K
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.4K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unraveling the spatial landscape of dystrophinopathies: a transcriptomic approach to Becker and Duchenne muscular dystrophies.

The Journal of pathology·2026
Same author

TREAT-NMD advisory committee for therapeutics: Preclinical and clinical learnings from 15 years of TACT.

Journal of neuromuscular diseases·2026
Same author

Myonuclear Domain-Associated and Central Nucleation-Dependent Spatial Restriction of Dystrophin Protein Expression.

Journal of cachexia, sarcopenia and muscle·2026
Same author

Report of the multistakeholder drug development round table meeting of the World Duchenne Organization focusing on challenges for clinical development of therapies.

Journal of neuromuscular diseases·2025
Same author

RNA therapies are delivering as therapies for neuromuscular dystrophy patients: Editorial for the special issue on RNA therapies in Journal of Neuromuscular Diseases.

Journal of neuromuscular diseases·2025
Same author

Individualized therapy development for rare diseases: individualized at every step of the way.

Therapeutic advances in rare disease·2025

Related Experiment Video

Updated: Jan 24, 2026

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

10.8K

Therapeutic developments for Duchenne muscular dystrophy.

Ingrid E C Verhaart1, Annemieke Aartsma-Rus2

  • 1Department of Human Genetics, Leiden University Medical Centre, Leiden, Netherlands.

Nature Reviews. Neurology
|June 1, 2019
PubMed
Summary
This summary is machine-generated.

Duchenne muscular dystrophy (DMD) treatments are advancing, with new gene therapies aiming to restore dystrophin protein. While current care slows progression, research focuses on therapies in clinical trials to combat muscle loss and improve patient outcomes.

More Related Videos

A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy
05:54

A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy

Published on: December 29, 2017

10.5K
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.2K

Related Experiment Videos

Last Updated: Jan 24, 2026

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

10.8K
A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy
05:54

A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy

Published on: December 29, 2017

10.5K
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.2K

Area of Science:

  • Biomedical research
  • Genetics
  • Neuromuscular disorders

Background:

  • Duchenne muscular dystrophy (DMD) results from absent functional dystrophin protein.
  • Despite improved care, DMD causes progressive muscle degeneration and premature death.
  • Effective therapies are urgently needed to halt disease progression.

Purpose of the Study:

  • To review recent advancements in Duchenne muscular dystrophy (DMD) therapeutic strategies.
  • To focus on emerging therapies in clinical trials and those already approved.
  • To provide an overview of gene-based and other promising treatment approaches.

Main Methods:

  • Review of current research and clinical trial data for DMD therapies.
  • Analysis of gene-addition, exon-skipping, and genome-editing approaches.
  • Examination of therapies targeting DMD pathogenesis pathways.

Main Results:

  • Several therapeutic strategies are in clinical development for DMD.
  • Gene therapies aim to restore partially functional dystrophin protein.
  • Other approaches focus on improving muscle function by targeting disease pathways.

Conclusions:

  • Significant progress is being made in developing novel DMD therapies.
  • Approved and investigational treatments offer new hope for patients.
  • Continued research is crucial for combating the effects of Duchenne muscular dystrophy.